The role of immune function in schizophrenia: An overview

European Archives of Psychiatry and Clinical Neuroscience

Volumn 249, Issue SUPPL. 4, 1999, Pages

  Müller, Norbert ^a   Riedel, Micheal ^a   Ackenheil, Manfred ^a   Schwarz, Markus J ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antipsychotics; Immune system; Psychoneuroimmunology; Schizophrenia

Indexed keywords

ANTIBODY; BUTYROPHENONE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; NEUROLEPTIC AGENT; PHENOTHIAZINE DERIVATIVE; SALMONELLOSIS VACCINE;

ANTIBODY PRODUCTION; B LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL FEATURE; CONFERENCE PAPER; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOPATHOLOGY; MACROPHAGE ACTIVATION; MONOCYTE; PRIORITY JOURNAL; SCHIZOPHRENIA; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

EID: 0041506093     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00014187     Document Type: Conference Paper

References (61)

1. Bessler H, Levental Z, Karp L, Modai I, Djaldetti M, Weizman A (1995) Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol Psychiatry 38: 297-302
2. Bruce LC, Peebles AMS (1903) Clinical and experimental observations on catatonia. J Mental Sci 49: 614-628
3. Bunney jr WE, Hamburg DA (1963) Methods for reliable longitudinal observation of behavior. Arch Gen Psychiatry 9: 280-294
4. Cazzullo CL, Scarone S, Grassi B, Vismara C, Trabattoni D, Clerici M, Clerici M (1998) Cytokines production in chronic-schizophrenia patients with or without paranoid behavior. Prog Neuro-Psychopharmacol Biol Psychiatry 22: 947-957
5. + lymphocytes in schizophrenic patients. Schizophrenia Res 31: 49-55
6. Dameshek W (1930) White blood cells in dementia praecox and dementia paralytica. Arch Neurol Psychiatry 24: 855
7. Dunn, AJ (1992) Endotoxin-induced activation of cerebral catecholamine and serotonin metabolism: comparison with interleukin-1. J Pharmacol Exp Ther 261: 964-969
8. Frei K, Malipiero UV, Leist TP, Zinkernagel RM, Schwab ME, Fontana A (1989) On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases Eur J Immunol 19: 689-694
9. Frommberger UH, Bauer J, Haselbauer P, Fraulin A, Riemann D, Berger M (1997) Interleukin-6 (IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry and Clin Neurosci 247: 228-232
10. Gallien M, Schnetzler JP, Morin J (1977) Antinuclear antibodies and lupus cells in 600 hospitalized phenothiazine treated patients. Ann Med Psychol Med 1: 237-248
11. Ganguli R, Rabin BS, Kelly RH, Lyte M, Ragu U (1987) Clinical and laboratory evidence of autoimmunity in acute schizophrenia. Ann NY Acad Sci 496: 676-685
12. Ganguli R, Yang Z, Shurin G, Chengappa R, Brar JS, Gubbi AV, Rabin BS (1994) Serum Interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res 51:1-10.
13. Ganguli R, Brar JS, Chengappa KR, DeLeo M, Yang ZW, Shurin G, Rabin B (1995) Mitogen-stimulated interleukin 2 production in never-medicated, first episode schizophrenics - the influence of age of onset and negative symptoms. Arch Gen Psychiatry 52: 878
14. Hama T, Kushima Y, Miyamoto M, Kubota M, Takei N, Hatanaka H (1991) Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures. Neurosci 40: 445-452
15. Hornberg M, Arolt V, Wilke I, Kruse A, Kirchner H (1995) Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia. Schizophrenia Res 15: 237-242
16. Kilidireas K, Latov N, Strauss DH, Aviva DG, Hashim GA, Gorman JM, Sadiq SA (1992) Antibodies to human 60 KD hear-shock protein in patients with schizophrenia. Lancet 340: 569-572
17. Körschenhausen D, Hampel H, Ackenheil M, Penning R, Müller N (1996) Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes. Schizophr Res 19: 103-109
18. Korte S, Arolt V, Peters M, Weitzsch Ch, Eckhoff D, Rothermund M, Kirchner H (1998) Increased serum neopterin levels in acutely ill and recovered schizophrenic patients. Schizophrenia Res 32: 63-67
19. Kuhlman P, Moy VT, Lollo BA, Brian AA (1991) The accessory function of murine intercellular adhesion molecule-1 in T-lymphocyte activation: contribution of adhesion and co-activation. J Immunol 146: 1773-1782
20. Lehmann-Facius H (1939) Serologisch-analytische Versuche mit Liquores und Seren von Schizophrenen. Allg Z Psychiatrie 110: 232-243
21. Lin A, Kenis G, Bignotti S, Tura GJB, De Jong R, Bosmans E, Pioli R, Altamura C, Scharpë S, Macs M (1998) The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophrenia Res 32: 9-15
22. Macs M, Meltzer HY, Bosmans E (1994) Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 89: 346-351
23. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY (1995) Interleukin-2 and Interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood-stabilizers. J Psychiatr Res 29: 141-152
24. Masserini C, Vita A, Basile R, Morselli R, Boato P, Peruzzi C, Pugnetti L, Ferrante P, Cazzullo CL (1990) Lymphocyte subsets in schizophrenic disorders. Relationship with clinical, neuromorphological and treatment variables. Schizophrenia Res 3: 269-275
25. + B-lymphocytes in schizophrenic patients. Arch Gen Psychiatry 46: 890-894
26. Mittleman BB, Castellanos FX, Jacobson LK, Rapoport JL, Swedo SE, Shearer GM (1997) Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J Immunol 159: 2994-2999
27. Molholm HB (1942) Hyposensitivity to foreign protein in schizophrenic patients. Psychiatr Quaterly 16: 565-571
28. Müller N, Ackenheil M (1995) Immunoglobulin and albumin contents of cerebrospinal fluid in schizophrenic patients: The relationship to negative symptomatology. Schizophrenia Res 14: 223-228
29. Müller N, Ackenheil M (1998) Psychoneuroimmunology, the cytokine network in the CNS, and the implications for psychiatric disorders. Progr Neuro-Psychopharmacol Biol Psychiatry 22: 1-31
30. Müller N, Ackenheil M, Hofschuster E, Mempel W, Eckstein R (1991) Cellular immunity in schizophrenic patients before and during neuroleptic therapy. Psychiatry Res 37:147-160
31. Müller N, Ackenheil M, Hofschuster E, Mempel W, Eckstein R (1993) T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy. Acta Psychiatr Scand 87: 66-71
32. Müller N, Empel M, Riedel M, Schwarz MJ, Ackenheil M (1997a) Neuroleptic treatment increases soluble 1L-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur Arch Psychiatry Clin Neurosci 247: 308-313
33. Müller N, Dohmeier P, Empel M, Riedel M, Schwarz M. Ackenheil M (1997b) Soluble IL-6 Receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients. Eur Psychiatry 12: 294-299
34. Müller N, Riedel M, Schwarz M, Gruber R, Ackenheil M (1997c) Immunomodulatory effects of neuroleptics to the cytokine system and the cellular immune system in schizophrenia. In: G. Wieselmann (ed) Current Update in Psychoimmunology, Springer Verlag Wien NY. pp 57-67
35. +) are elevated in unmedicated schizophrenic patients and related to the blood-brain barrier and the HLA allele DPA 02011. Schizophrenia Res 12: 69-71
36. Müller N, Hadjamu M, Riedel M, Primbs J, Ackenheil M, Gruber R (1999) The adhesion-molecule receptor expression on T helper cells increases during treatment with neuroleptics and is related to the blood-brain barrier permeability in schizophrenia. Am J Psychiatry 156: 634-636
37. Muraguchi A, Hirano T, Tang B, Matsuda T, Horii Y, Nakajima K, Kishimoto T (1988) The essential role of B-cell stimulating factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells J Exp Med 167: 332-344
38. Narazaki M, Yasukawa K, Saito T et al (1993) Soluble forms of the interleukin-6-signal transducing receptor component of gp 130 in human serum possessing a potential to inhibit signals through membrane anchored gp 130. Blood 82: 1120-1126
39. Neidhart M, Pataki F, Fehr K (1995) Increased soluble endothelial adhesion molecules in rheumatoid arthritis correlate with circulating cytokines and depletion of CD45R0+ T-lymphocytes from blood stream. Schweiz Med Wochenschr 125:424-428
40. Özek M, Töreci K, Akkök I, Güvener Z (1971) The influence of treatment with neuroleptics upon the antibody-formation. Psychopharmacologia 21: 401-412
41. Plata-Salaman CR (1991) Immunoregulators in the nervous system. Neurosci Behav Rev 15: 185-215
42. Pollmächer T, Hinze-Selch D, Mullington J, Holsboer F (1995) Clozapine-induced increase in plasma levels of soluble Interleukin-2 receptors. Arch Gen Psychiatry 52: 877-878
43. Ramchand R, Wei J, Ramchand CN, Hemmings GP (1994) Increased serum IgE in schizophrenic patients who responded poorly to neuroleptic treatment. Life Sci 54: 1579-1584
44. Rothermund M, Arolt V, Weitzsch Ch, Eckhoff D, Kirchner H (1996) Production of cytokines in acute schizophrenic psychosis. Biol Psychiatry 1294-1297
45. Saunders JC, Muchmore E (1964) Phenothiazine effect on human antibody synthesis. Br J Psychiatry 110: 84-89
46. Schwarz MJ, Ackenheil M, Riedel M, Müller N (1998a) Blood-CSF-Barrier impairment as indicator for an immune process in schizophrenia. Neurosci Letters 253: 201-203
47. Schwarz MJ, Riedel M, Gruber R, Müller N, Ackenheil M (1998b) Autoantibodies against 60-kDa heat shock protein in schizophrenia. Eur Arch Psychiatry Clin Neurosci 248: 282-288
48. Schwarz MJ, Riedel M, Gruber R, Ackenheil M, Müller N (1999a) Antibodies to heat-shock proteins in schizophrenic patients -Implications for disease mechanism. Am J Psychiatry 156: 1103-1104
49. Schwarz MJ, Riedel M, Ackenheil M, Müller N (1999b) Deceased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biol Psychiatry (in press)
50. Schwarz MJ, Müller N, Riedel M, Trapman H, Ackenheil M (1999c) Altered regulation of Interleukin-6 in CSF of schizophrenic patients. Am J Psychiatry (submitted)
51. Spangelo BL, Judd AM, Isakson PC, MacLeod, RM (1989) Interleukin-6 stimulates anterior pituitary hormone release in vitro Endocrinology 125: 575-577
52. Sperner-Unterweger B, Barnas Ch, Fuchs D, Kemmler G, Wachter H, Hinterhuber H, Fleischhacker WW (1992) Neopterin production in acute schizophrenic patients: an indicator of alterations of cell-mediated immunity. Psychiatry Res 42: 121-128
53. Sperner-Unterweger B, Miller C, Holzner B, Widner B, Fleischhacker WW, Fuchs D (1999) Measurement of neopterin, kynurenine and tryptophan in sera of schizophrenic patients. In: Müller N (ed) Psychiatry, Psychimmunology, and Viruses. Springer Wien, NY, pp 115-119
54. Van Kammen DP, McAllister-Sistilli CG, Kelley ME (1997) Relationship between immune and behavioral measures in schizophrenia. In: G. Wieselmann (ed) Current Update in Psychoimmunology, Springer Verlag Wien, NY, pp 51-55
55. Van Kammen DP, McAllister-Sistilli CG, Kelley ME, Gurklis JA, Yao JK (1999) Methodological concerns in the study of the immune system in schizophrenia. In: Müller N (ed) Psychiatry, Psychimmunology, and Viruses. Springer Wien, NY, pp 63-69
56. Van Seventer GA, Shimizu Y, Horgan KJ, Shaw S (1990) The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T-cell receptor mediated activation of resting T-cells. J Immunol 144: 4579-4586
57. Villemain F, Chatenoud L, Galinowski A, Homo-Delarche F, Genestet D, Loo H, Zarifarain E, Bach JF (1989) Aberrant T-cell-mediated immunity in untreated schizophrenic patients: Deficient Interleukin-2 production. Am J Psychiatry 146: 609-616
58. Vinogradov S, Gottesman II, Moises HW, Nicol S (1991) Negative association between schizophrenia and rheumatoid arthritis. Schizophr Bull 17: 669-678
59. Wilke I, Arolt V, Rothermundt M, Weitzsch Ch, Hornberg M, Kirchner H (1996) Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 246: 279-284
60. Zalcman S, Green-Johnson JM, Murray L, Nance DM, Dyck D, Anisman H, Greenberg AH (1994) Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res 643: 40-49
61. Zarrabi MH, Zucker S, Miller F, Derman RM, Romeno GS, Hartnett JA, Varma AO (1979) Immunologic and coagulation disorders in chlorpromazine-treated patients. Ann Int Med 91: 194-199